Heart Failure
In HF, possible longer-term benefits emerge with remote management strategy
Among adults with HF, temporary exposure to a remote patient monitoring strategy was not associated with lower risk for all-cause death or hospitalization compared with usual care, though some longer-term benefits were observed, data show.
Adequate hydration may slow biological aging, reduce disease risk
Adults with elevated serum sodium in middle age, a marker of inadequate fluid intake, were more likely to be biologically older than their chronological age and develop chronic diseases compared with adequately hydrated adults, data show.
Framingham dementia risk score ‘appropriate’ predictor of Alzheimer’s disease in HF, AF
Variables from the Framingham Dementia Risk Score are an accurate predictor of Alzheimer’s disease or without the addition of other variables, researchers reported.
HF prevalence may be higher than estimates in low- to middle-income countries
The age-standardized prevalence of HF in low- to middle-income countries may be much higher than modeling estimates suggest and signals the persistence of global CVD health disparities, according to researchers.
Nearly half of HF cases undiagnosed before noncardiac surgery
Data from a medical records review suggest that nearly half of cases of preoperative HF remain undiagnosed before patients undergo noncardiac surgery, suggesting efforts to improve preoperative diagnosis are needed.
Q&A: How a gut-derived metabolite may predict incidence, severity of HF
Research suggests a potential mechanistic link between the gut microbiome and HF development, with new data demonstrating that levels of a gut-derived metabolite may track with HF risk and multiple indices of HF severity.
Top in cardiology: FDA panel declines heart failure drug; risks of extreme temperatures
An FDA advisory committee declined to support an approval for the heart failure drug omecamtiv mecarbil, citing narrow benefits of the drug.
Pipeline Pulse: A look at tirzepatide, ziltivekimab and obicetrapib
The field of cardiology has seen stunning advances in the past several years: HF, dyslipidemia and cardiomyopathy are just three of the disorders in which there have been recent practice-changing therapeutic innovations.
High body water mass associated with risk for sleep apnea
Individuals with high body water mass appeared to have an increased risk for sleep apnea, possibly mediated by pathologic edema, according to a study published in Annals of the American Thoracic Society.
New data, updated guidance ‘dramatically’ changing HF treatment landscape
Treatment of HF has evolved rapidly in recent years, with novel therapies and a fundamentally new treatment algorithm offering options for improved management of the disease across the full spectrum of ejection fraction.